Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lu AF35700

Drug Profile

Lu AF35700

Alternative Names: Lu-AF35700

Latest Information Update: 17 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lundbeck A/S
  • Class Neuropsychotherapeutics
  • Mechanism of Action Dopamine D1 receptor modulators; Serotonin 2A receptor modulators; Serotonin-6 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Schizoaffective disorder; Schizophrenia

Most Recent Events

  • 10 Oct 2019 Lundbeck A/S completes the phase III Debut trial for Schizophrenia (Treatment-resistant) in USA, Canada, Bulgaria, Czech Republic, Estonia, Mexico, Poland, Romania, Russia, Serbia, Slovakia, Spain and Ukraine (NCT02892422)
  • 26 Sep 2019 H. Lundbeck A/S terminates a phase I trial in Schizophrenia (In volunteers) in Germany based on new efficacy data (PO) (NCT03241147)
  • 14 Aug 2019 Discontinued - Phase-I for Schizoaffective disorder in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top